BioArctic

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on treatments that can delay or stop the progression of neurodegenerative diseases. BioArctic invented the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. In addition, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer and Parkinson projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. GDPR information: https://www.bioarctic.se/en/social-media-privacy-policy/ Beware of Fraudulent job offers Some individuals have received messages that appear to be legitimate employment offers from BioArctic, but these messages are fraudulent. This type of fraud, known as "phishing," targets businesses worldwide. The perpetrators typically aim to obtain personal or bank information or to extract money for processing job applications, work permits, or visa-related costs. These messages may seem authentic, using company logos or personal details from social media but they are not connected to nor are they from BioArctic. We do not use such methods in our recruitment processes. A genuine job offer from BioArctic always follows a formal application and personal interviews.